Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
FEMS Yeast Res. 2010 Dec;10(8):1060-9. doi: 10.1111/j.1567-1364.2010.00665.x.
The ultimate goal of therapeutic vaccines is to activate and exploit the patient's own immune system to vigorously and dynamically seek and eradicate established malignant or virally infected cells. Therapeutic vaccines also offer the potential for preventing disease recurrence. Saccharomyces cerevisiae-based vaccines, where the yeast is engineered to express viral or tumor antigens, represent an ideal therapeutic approach due to their ability to stimulate tumor- or viral-specific CD4(+) and CD8(+) T-cell responses that are capable of reducing disease burden. This review describes preclinical and clinical studies supporting the development of S. cerevisiae-based therapeutic vaccines for the treatment of cancer and viral diseases, as well as multimodal strategies in which therapeutic vaccines are combined with cytotoxic drugs to achieve a greater clinical response.
治疗性疫苗的最终目标是激活和利用患者自身的免疫系统,积极主动地寻找并清除已建立的恶性或病毒感染细胞。治疗性疫苗还有预防疾病复发的潜力。基于酿酒酵母的疫苗通过工程改造使酵母表达病毒或肿瘤抗原,由于其能够刺激肿瘤或病毒特异性 CD4(+)和 CD8(+)T 细胞反应,从而降低疾病负担,因此代表了一种理想的治疗方法。本综述描述了支持开发基于酿酒酵母的治疗性疫苗治疗癌症和病毒疾病的临床前和临床研究,以及将治疗性疫苗与细胞毒性药物联合使用以实现更大临床反应的多模态策略。